rubitecan

04/01/2011 - "The purpose of this study is to evaluate the pharmacokinetics and safety of 9-nitrocamptothecin in patients with advanced solid tumors. "
04/01/2011 - "A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors."
12/01/2004 - "Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors."
08/01/2004 - "Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors."
08/01/2004 - "The results of this study do not suggest further investigation of RFS2000 at the present dose and schedule for the treatment of urothelial tract tumors in this refractory population."

07/01/2005 - "9-Nitrocamptothecin has completed phase III studies in patients with newly diagnosed and refractory pancreatic cancer; however, the optimal 9-nitrocamptothecin treatment regimen is unclear. "
03/01/2005 - "Phase II trial of oral rubitecan in previously treated pancreatic cancer patients."
05/01/1999 - "A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer."
03/01/2005 - "Oral rubitecan produced responses and was well tolerated by heavily pretreated patients with refractory pancreatic cancer. "
01/01/2004 - "In June 2003, the EMEA granted SuperGen orphan drug status for rubitecan for the treatment of pancreatic cancer. "

02/01/1994 - "Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro."
08/01/1999 - "After in-vitro exposure to 0.05 micromol/L 9-nitrocamptothecin (9NC) for periods of time longer than 5 days, 65% to 80% of the human malignant melanoma SB1B cells die by apoptosis, whereas the remaining cells are arrested at the G2-phase of the cell cycle. "
08/01/1999 - "Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro."
10/01/2002 - "Rubitecan in IDD-P, a particulate suspension of the insoluble analog, produced significant tumor growth delay in athymic nude mice bearing A375 melanoma, and MX-1 breast, SKMES non-small-cell lung, Panc-1 pancreatic and HT29 colon carcinomas. "
02/01/2003 - "Particularly, ester 5b demonstrated an antitumor activity against a broad spectrum of human carcinomas including breast, lung, colon, pancreas, stomach, ovarian, and melanoma, etc. These esters act like prodrugs of their parental 9-nitrocamptothecin. "

03/01/2002 - "Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin."
07/01/2000 - "To determine whether this approach has utility against pulmonary metastases, the efficacy of aerosol therapy with liposome-encapsulated 9-nitrocamptothecin (L-9NC) was determined using two different experimental lung metastasis models. "
07/01/2000 - "9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice."
01/01/2000 - "9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice."
03/01/2002 - "We previously demonstrated that aerosol delivery of dilauroylphosphatidylcholine liposome formulation of 9-nitrocamptothecin (9NC-DLPC) inhibits B16-F10 melanoma lung metastases. "

01/01/2004 - "Results from an ongoing phase II study in cancer patients have shown that rubitecan was effective against chordomas, a rare type of bone cancer. "
07/01/2013 - "We identified a group of drugs including bortezomib, 17-AAG, digitoxin, staurosporine, digoxin, rubitecan, and trimetrexate that inhibited chordoma cell growth, with potencies from 10 to 370 nM in U-CH1 cells, but less potently in U-CH2 cells. "